

Supplementary Table: Clinical and pathological features of PSP-C patients

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5
Sex	Female	Female	Male	Male	Female
Age at onset	62	74	66	73	64
Age at death	71	81	74	79	82
Initial Sx	ataxic gait	ataxic gait, ataxic speech	ataxic gait, ataxic speech, syncope	ataxic gait, CI	ataxic gait, ataxic speech
Other Sx	limb ataxia, fall, rigidity, VGP, dysarthria, PS, UI, dizziness, CI	limb ataxia, fall, SS, parkinsonian gait, PS, CI, dysphasia	limb ataxia, postural instability, rigidity, bradykinesia, PS, CI	limb ataxia, rigidity, fall, SS, dysarthria, dysphasia, PS	limb ataxia, fall, SS, UI, CI, dysphasia
Initial Dx	Alcohol ataxia	MSA-C	MSA-C	PN + AD	Vit.B12 deficiency
Final Dx	MSA-C	MSA-C	MSA-C	PSP	MSA-C
Pathologic Dx	PSP	PSP/AGD	PSP	PSP/AD/IOH	PSP/AGD/AD/CD
Brain weight (g)	1060	1140	1280	1080	1180
Braak NFT stage	0	4	0	5	4
Thal amyloid phase	0	0	0	3	5

Abbreviations: PSP, progressive supranuclear palsy; PSP-C, PSP with predominant cerebellar ataxia; Sx, symptom; Dx, diagnosis; NFT, neurofibrillary tangles; VGP, vertical gaze palsy; PS, pyramidal signs; UI, urinary incontinence; CI, cognitive impairment; SS, slow saccades; MSA-C, multiple system atrophy with predominant cerebellar ataxia; PN, Peripheral neuropathy; Vit.B12, vitamin B12; AD, Alzheimer disease; AGD, argyrophilic grain disease; IOH, inferior olivary hypertrophy; CD, cerebellar degeneration.